Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
<!-- Name:DistributionId Value:8810464 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
AB729
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD –…
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1…
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and…
Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Arbutus…
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International…
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients.…
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD…
Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to 28 weeks after discontinuation of…
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five…
AB-729, dosed at 60 mg every 8 weeks, achieved a mean HBsAg decline of -1.87 log10 IU/mL at week 44, comparable to 60 mg dosed every 4 weeks AB-729 resulted in HBsAg declines below 100…